← Eichor
Study identifier: NCT06731764 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Novel Approaches to the Treatment of Hypothyroidism

Condition: Hypothyroidism  ·  Sponsor: UConn Health

PhasePhase 2/Phase 3
Planned participants90
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Hypothyroidism is a common condition, more frequent in females, associated with excess of cardiovascular risk and poor quality of life not completely abrogated by treatment with levothyroxine. There is an unmet need to define a safe, effective, and feasible regimen to be applied in large trials aimed at assessing levothyroxine/liothyronine combination therapy in patients living with hypothyroidism. To address this knowledge gap we propose a randomized, three-arm, double-blind, controlled, escalating dose parallel pilot study whose results will lay the foundation of large multicenter trial(s) able to demonstrate the effectiveness (or lack thereof) of levothyroxine/liothyronine combination therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Francesco S Celi, MD, MHSc.  ·  (860) 679-2715  ·  celi@uchc.edu

Nicole Glidden  ·  (860) 679-4647  ·  DOMClinicalResearch@uchc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UConn HealthFarmington, Connecticut, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06731764